PierPaolo Peruzzi, Ph.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 11 | 2022 | 3357 | 1.410 |
Why?
|
| MicroRNAs | 6 | 2019 | 3680 | 0.960 |
Why?
|
| Brain Neoplasms | 10 | 2021 | 8805 | 0.860 |
Why?
|
| Poliovirus | 1 | 2018 | 108 | 0.680 |
Why?
|
| Glioma | 4 | 2013 | 3299 | 0.620 |
Why?
|
| Comovirus | 1 | 2015 | 5 | 0.600 |
Why?
|
| Neurosurgery | 1 | 2021 | 635 | 0.550 |
Why?
|
| Genetic Engineering | 2 | 2019 | 957 | 0.540 |
Why?
|
| Vestibular Nerve | 1 | 2014 | 102 | 0.520 |
Why?
|
| Transgenes | 2 | 2019 | 1021 | 0.420 |
Why?
|
| Neuroma, Acoustic | 1 | 2014 | 441 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 8685 | 0.410 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 1332 | 0.380 |
Why?
|
| Craniotomy | 2 | 2011 | 728 | 0.370 |
Why?
|
| Supratentorial Neoplasms | 1 | 2010 | 159 | 0.360 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 347 | 0.350 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 127 | 0.350 |
Why?
|
| Electromagnetic Fields | 1 | 2010 | 306 | 0.340 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1004 | 0.340 |
Why?
|
| Oncolytic Virotherapy | 3 | 2022 | 455 | 0.340 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2009 | 119 | 0.330 |
Why?
|
| Conscious Sedation | 1 | 2010 | 510 | 0.280 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 1003 | 0.280 |
Why?
|
| Fetal Diseases | 1 | 2010 | 900 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1391 | 0.270 |
Why?
|
| Wakefulness | 1 | 2011 | 1178 | 0.250 |
Why?
|
| Nanoparticles | 1 | 2015 | 1942 | 0.250 |
Why?
|
| Monitoring, Intraoperative | 1 | 2011 | 959 | 0.250 |
Why?
|
| Central Nervous System | 1 | 2010 | 1292 | 0.240 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 869 | 0.230 |
Why?
|
| Anesthesia, General | 1 | 2010 | 1103 | 0.230 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2010 | 1600 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 937 | 0.230 |
Why?
|
| Nervous System Diseases | 2 | 2010 | 1645 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 2081 | 0.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2019 | 645 | 0.200 |
Why?
|
| Cell Movement | 2 | 2013 | 5465 | 0.190 |
Why?
|
| Oncolytic Viruses | 1 | 2022 | 294 | 0.170 |
Why?
|
| Gamma Rays | 1 | 2019 | 335 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2011 | 34502 | 0.150 |
Why?
|
| Genetic Vectors | 3 | 2019 | 3555 | 0.150 |
Why?
|
| Histone Demethylases | 1 | 2019 | 304 | 0.150 |
Why?
|
| Cloning, Molecular | 1 | 2019 | 4483 | 0.120 |
Why?
|
| Neuroglia | 1 | 2019 | 920 | 0.120 |
Why?
|
| Melanoma | 1 | 2011 | 5260 | 0.120 |
Why?
|
| Humans | 23 | 2022 | 717237 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2011 | 15126 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2019 | 3830 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2014 | 23996 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2759 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3697 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 2034 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2021 | 2125 | 0.090 |
Why?
|
| Anesthesia, Inhalation | 1 | 2010 | 226 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 605 | 0.090 |
Why?
|
| Neurons | 1 | 2009 | 9441 | 0.090 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2009 | 131 | 0.090 |
Why?
|
| Exosomes | 1 | 2013 | 408 | 0.090 |
Why?
|
| Animals | 9 | 2019 | 170890 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2009 | 202 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 327 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 8013 | 0.080 |
Why?
|
| Etoposide | 1 | 2009 | 630 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2010 | 999 | 0.080 |
Why?
|
| Vincristine | 1 | 2009 | 1043 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3100 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2010 | 588 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 818 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 713 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1531 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3469 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 651 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2019 | 10542 | 0.070 |
Why?
|
| Prednisone | 1 | 2009 | 1548 | 0.070 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 1666 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 16989 | 0.060 |
Why?
|
| Hydrocephalus | 1 | 2010 | 734 | 0.060 |
Why?
|
| Mice | 4 | 2019 | 81126 | 0.060 |
Why?
|
| Phenotype | 1 | 2021 | 16404 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 2193 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2010 | 1512 | 0.060 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 684 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9532 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2009 | 2235 | 0.060 |
Why?
|
| Methotrexate | 1 | 2009 | 1732 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2019 | 10802 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2011 | 1350 | 0.050 |
Why?
|
| Gestational Age | 1 | 2010 | 3427 | 0.050 |
Why?
|
| Female | 7 | 2019 | 377909 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3778 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 8943 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5101 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 2566 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2022 | 596 | 0.050 |
Why?
|
| tau Proteins | 1 | 2009 | 1645 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 346 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 39302 | 0.040 |
Why?
|
| Prognosis | 3 | 2019 | 29226 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8923 | 0.040 |
Why?
|
| Critical Care | 1 | 2010 | 2497 | 0.040 |
Why?
|
| Length of Stay | 1 | 2010 | 6280 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 72614 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11336 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 14903 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11777 | 0.030 |
Why?
|
| Adult | 4 | 2022 | 212451 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2011 | 62348 | 0.030 |
Why?
|
| Microglia | 1 | 2022 | 1173 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2013 | 12073 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2009 | 20095 | 0.030 |
Why?
|
| Male | 4 | 2011 | 351380 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 19538 | 0.030 |
Why?
|
| Rats | 1 | 2009 | 25091 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 9597 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 341 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 3698 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 27306 | 0.020 |
Why?
|
| Biological Transport | 1 | 2013 | 2136 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 39887 | 0.020 |
Why?
|
| Aged | 2 | 2010 | 162856 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2022 | 4137 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13754 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 20568 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 1730 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6564 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3704 | 0.020 |
Why?
|
| Simplexvirus | 1 | 2009 | 813 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2716 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1474 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 85139 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 8013 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29491 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 215041 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 18352 | 0.010 |
Why?
|